预约演示
更新于：2026-02-27
Entacapone
恩他卡朋
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (1998-09-16), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C14H15N3O5 |
InChIKeyJRURYQJSLYLRLN-BJMVGYQFSA-N |
CAS号130929-57-6 |
关联
41
项与 恩他卡朋 相关的临床试验TCTR20250905008
A Single Dose, Randomized, Open-label, Four-period, Replicate Crossover Bioequivalence Study of Generic Entacapone 200 mg Film-coated Tablets and Reference Product (Comtan) in Healthy Thai Volunteers under Fasting Conditions
CTR20253873
恩他卡朋片在中国健康研究参与者中空腹和餐后状态下随机、开放、单剂量、两序列、四周期、重复交叉生物等效性研究
ChiCTR2500104562
Exploratory Clinical Study ofEntacapone Combined with PD-1/1Antibody andTargeted Therapy in Advanced Hepatocellular Carcinoma Refractory to StandardTreatment
100 项与 恩他卡朋 相关的临床结果
登录后查看更多信息
100 项与 恩他卡朋 相关的转化医学
登录后查看更多信息
100 项与 恩他卡朋 相关的专利（医药）
登录后查看更多信息
943
项与 恩他卡朋 相关的文献（医药）2026-03-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Voltammetric analysis of entacapone, levodopa, and carbidopa in tablets: A chemometric approach
Article
作者: Budak, Fatma ; Cetinkaya, Ahmet ; Safarnejad, Azam ; Dogan-Topal, Burcu ; Ozkan, Sibel A
The objective of the present work is to develop a voltammetric method for the determination of entacapone (ENT) in the presence of levodopa (LEV) and carbidopa (CAR) in synthetic mixtures and pharmaceutical formulations, using a multivariate approach. ENT is an inhibitor of Catechol-O-methyltransferase (COMT), used in the treatment of Parkinson's disease as an adjunct for the combination therapy with LEV and CAR. With the optimized parameters in a pH 3.0 Britton-Robinson buffer, the quantitative analyses were assessed by the root mean square error in prediction (RMSEP), as well as the root mean square error of calibration (RMSEC) and the relative error of prediction (REP). The Radial Basis Function Artificial Neural Network (RBF-ANN) and Partial Least Squares regression (PLS) were applied for the determination of ENT in the presence of LEV and CAR. In the RBF-ANN model, the REP of 0.87 and RMSEP of 2.14×10-7 are obtained for the test data when quantifying the ENT. The RBF model, as a nonlinear calibration method, was successful for predicting ENT concentration. To evaluate the validity of the recommended method, a commercial pharmaceutical tablet (Stalevo ® 200 mg) was analyzed. RBF model has the ability to overcome difficulties such as non-linearity and overlaps in the voltammograms.
2026-02-01JOURNAL OF NEURAL TRANSMISSION
COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion
Review
作者: Nyholm, Dag ; Jenner, Peter
Abstract:
Enhancing levodopa efficacy through peripheral COMT inhibition and using continuous infusion are both established strategies for managing motor fluctuations. Both approaches aim to improve the pharmacokinetics of levodopa in order to maintain a steady delivery of levodopa to the brain, avoid the deep troughs in levodopa plasma concentrations associated with oral levodopa delivery, and thereby reduce OFF time. In this review, we describe the pharmacologic rationale for combining COMT inhibition with entacapone and continuous dopaminergic delivery that led to the development of levodopa/entacapone/carbidopa intestinal gel (LECIG). Entacapone is a peripheral COMT inhibitor, that effectively reduces the metabolism of levodopa to 3-O-methyldopa and increases the amount of levodopa that can be transported into the brain. However, entacapone has a short half-life and poor oral bioavailability that necessitates frequent dosing for optimal efficacy. Continuous infusion of entacapone allows for improved bioavailability from direct delivery to the duodenum/jejunum. As such, lower overall levodopa doses can be given to achieve therapeutically effective concentrations. Accumulating real-world evidence with LECIG supports its use in managing motor fluctuations in patients whose control is becoming suboptimal with oral approaches. We provide an overview of the growing evidence base for its risk-benefit profile in patients with motor fluctuations.
2026-02-01LUMINESCENCE
Biogenic Silver Nanoparticles via Microwave‐Assisted Green Synthesis: Antimicrobial Agents and Fluorescent Nanosensors for the Sensitive Determination of Entacapone and Thiopental in Human Plasma and Dosage Forms
Article
作者: Magdy, Galal ; Belal, Fathalla ; Said, Noura ; Shehab El‐Din, Eman M. Rabie
ABSTRACT:
In this work, silver nanoparticles (Ag‐NPs) were developed as sensitive fluorescent nanoprobes for the assay of entacapone and thiopental, for the first time. Ag‐NPs were synthesized via an ultrafast microwave‐assisted green method in only 30 s using
Lupinus albus
seed extract as a natural reducing agent. The prepared Ag‐NPs were characterized using high‐resolution transmission electron microscope, dynamic light scattering, energy‐dispersive X‐ray spectroscopy, Fourier transform infrared, UV–visible spectrophotometry, and spectrofluorimetry. They exhibited strong intrinsic fluorescence at 360 nm upon excitation at 280 nm, with a mean particle size of 38.3 nm and a polydispersity index of 0.202. The native fluorescence of Ag‐NPs was selectively quenched by entacapone and thiopental over concentration ranges of 0.8–10.0 and 5.0–20.0 μM, with detection limits of 0.07 and 0.52 μM, respectively. The proposed nanosensor was successfully applied for the determination of both drugs in pharmaceutical dosage forms and spiked human plasma. In addition to their analytical performance, the synthesized Ag‐NPs demonstrated significant antimicrobial activity against one fungal strain and four bacterial strains. This dual functionality highlights their potential as a multifunctional theranostic detect‐and‐treat nanoplatform integrating diagnostic sensing with antimicrobial action. The greenness of the method was assessed using AGSA and ComplexMoGAPI tools, and the method was validated according to ICH Q2(R2) guidelines.
100 项与 恩他卡朋 相关的药物交易
登录后查看更多信息
研发状态
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 551 | 鬱網觸艱蓋壓窪構廠艱(鑰繭夢顧鑰願艱餘憲鹹) = 遞選醖簾積製衊醖遞構 範憲願鑰鹹選積鹹艱膚 (壓繭鹽鏇艱顧鹽艱繭鏇 ) 更多 | - | 2015-12-01 | ||
鬱網觸艱蓋壓窪構廠艱(鑰繭夢顧鑰願艱餘憲鹹) = 網網糧夢觸顧艱憲範遞 範憲願鑰鹹選積鹹艱膚 (壓繭鹽鏇艱顧鹽艱繭鏇 ) 更多 | |||||||
临床1/2期 | 14 | (LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT) | 顧艱憲觸艱齋簾築艱窪(蓋鑰齋糧窪壓夢選夢襯) = 膚鹽願鬱選簾醖範淵鑰 鏇網築鑰醖夢鹹憲簾襯 (壓蓋憲積齋顧齋鬱遞製, 廠顧膚膚憲淵遞網鑰餘 ~ 襯網襯醖襯蓋鏇淵醖積) 更多 | - | 2014-07-17 | ||
(LDOPS + Placebo; LDOPS + Ent; LDOPS + CAR) | 顧艱憲觸艱齋簾築艱窪(蓋鑰齋糧窪壓夢選夢襯) = 醖衊壓蓋襯淵獵襯簾餘 鏇網築鑰醖夢鹹憲簾襯 (壓蓋憲積齋顧齋鬱遞製, 簾齋襯願繭築淵選窪觸 ~ 鹹鬱膚願願憲齋憲壓獵) 更多 | ||||||
N/A | - | Immediate Switch to Levodopa/Carbidopa/Entacapone | 構醖廠衊鏇憲膚糧廠鹽(憲淵繭壓築簾鹽範顧遞) = 築簾鏇獵鏇鬱鹽繭願膚 繭簾鑰繭衊遞鏇窪餘獵 (鑰糧鹽衊齋壓齋醖醖蓋 ) 更多 | 积极 | 2011-10-13 | ||
Delayed Switch to Levodopa/Carbidopa/Entacapone | 構醖廠衊鏇憲膚糧廠鹽(憲淵繭壓築簾鹽範顧遞) = 夢衊膚蓋構艱廠膚製鑰 繭簾鑰繭衊遞鏇窪餘獵 (鑰糧鹽衊齋壓齋醖醖蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用